Avalo Therapeutics, Inc. (AVTX)
16.12
-1.06
(-6.17%)
USD |
NASDAQ |
Sep 11, 16:00
16.11
-0.01
(-0.06%)
After-Hours: 20:00
Avalo Therapeutics Enterprise Value : 454.68M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 454.68M |
| September 10, 2026 | 510.75M |
| September 09, 2026 | 565.24M |
| September 08, 2026 | 644.59M |
| September 04, 2026 | 619.20M |
| September 03, 2026 | 607.03M |
| September 02, 2026 | 625.02M |
| September 01, 2026 | 604.39M |
| August 31, 2026 | 625.02M |
| August 28, 2026 | 638.24M |
| August 27, 2026 | 662.58M |
| August 26, 2026 | 689.03M |
| August 25, 2026 | 646.18M |
| August 24, 2026 | 621.31M |
| August 21, 2026 | 650.94M |
| August 20, 2026 | 650.41M |
| August 19, 2026 | 699.61M |
| August 18, 2026 | 644.59M |
| August 17, 2026 | 657.29M |
| August 14, 2026 | 638.24M |
| August 13, 2026 | 630.84M |
| August 12, 2026 | 636.13M |
| August 11, 2026 | 631.89M |
| August 10, 2026 | 647.76M |
| August 07, 2026 | 571.06M |
| Date | Value |
|---|---|
| August 06, 2026 | 591.16M |
| August 05, 2026 | 598.57M |
| August 04, 2026 | 582.17M |
| August 03, 2026 | 556.77M |
| July 31, 2026 | 567.35M |
| July 30, 2026 | 627.66M |
| July 29, 2026 | 607.56M |
| July 28, 2026 | 634.54M |
| July 27, 2026 | 633.48M |
| July 24, 2026 | 577.41M |
| July 23, 2026 | 541.43M |
| July 22, 2026 | 562.06M |
| July 21, 2026 | 597.51M |
| July 20, 2026 | 565.24M |
| July 17, 2026 | 626.60M |
| July 16, 2026 | 547.78M |
| July 15, 2026 | 583.22M |
| July 14, 2026 | 576.35M |
| July 13, 2026 | 602.27M |
| July 10, 2026 | 618.14M |
| July 09, 2026 | 657.29M |
| July 08, 2026 | 618.14M |
| July 07, 2026 | 620.26M |
| July 06, 2026 | 657.82M |
| July 02, 2026 | 598.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Incyte Corp. | 19.92B |
| AbbVie, Inc. | 518.65B |
| Rezolute, Inc. | 287.20M |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.36M |
| Total Expenses (Quarterly) | 36.36M |
| EPS Diluted (Quarterly) | -0.8339 |
| Earnings Yield | -29.40% |
| Normalized Earnings Yield | -26.07 |